{"id":61547,"date":"2026-03-27T13:26:40","date_gmt":"2026-03-27T05:26:40","guid":{"rendered":"https:\/\/flcube.com\/?p=61547"},"modified":"2026-03-27T13:26:41","modified_gmt":"2026-03-27T05:26:41","slug":"hengrui-pharmas-hrs9531-wins-nmpa-approval-for-cardiovascular-outcomes-trial-dual-gipr-glp-1r-agonist-targets-mace-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61547","title":{"rendered":"Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial \u2013 Dual GIPR\/GLP-1R Agonist Targets MACE Reduction"},"content":{"rendered":"\n

Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (SHA: 600276<\/a>, HKG: 1276<\/a>) received National Medical Products Administration (NMPA) approval<\/strong> to initiate a clinical study of HRS9531<\/strong> for reducing major adverse cardiovascular events (MACE)<\/strong> in patients with atherosclerotic cardiovascular disease (ASCVD)<\/strong>. The innovative dual GIPR\/GLP-1R agonist<\/strong>, already approved for weight reduction and chronic kidney disease<\/strong> trials, now targets cardiovascular outcomes<\/strong> \u2013 a globally unprecedented indication<\/strong> for this drug class, with potential benefits via weight loss, glycemic control, and direct mechanisms<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Clinical trial authorization (IND)<\/td><\/tr>
Product<\/strong><\/td>HRS9531 \u2013 dual GIPR\/GLP-1R agonist<\/td><\/tr>
Developer<\/strong><\/td>Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276)<\/td><\/tr>
New Indication<\/strong><\/td>MACE reduction in ASCVD patients<\/strong><\/td><\/tr>
Previous Approvals<\/strong><\/td>Weight reduction; chronic kidney disease<\/td><\/tr>
Global Significance<\/strong><\/td>No similar drug approved globally for this indication<\/strong> \u2013 first-in-class potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Target<\/th>HRS9531 Action<\/th>Therapeutic Effect<\/th><\/tr><\/thead>
GIPR (Gastric Inhibitory Polypeptide Receptor)<\/strong><\/td>Dual agonism with GLP-1R<\/td>Enhanced metabolic regulation<\/strong> \u2013 glucose\/lipid metabolism optimization<\/td><\/tr>
GLP-1R (Glucagon-Like Peptide-1 Receptor)<\/strong><\/td>Dual agonism with GIPR<\/td>Appetite suppression<\/strong>, insulin sensitivity improvement<\/strong>, weight loss<\/strong><\/td><\/tr>
Cardiovascular Mechanism<\/strong><\/td>Indirect<\/strong>: weight loss + glycemic control; Potential direct<\/strong>: vascular effects<\/td>MACE reduction<\/strong> \u2013 heart attack, stroke, cardiovascular death prevention<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Position<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
GLP-1 Cardiovascular Validation<\/strong><\/td>Semaglutide (SELECT trial)<\/strong> demonstrated 20% MACE reduction in obesity; tirzepatide (SURPASS-CVOT)<\/strong> ongoing \u2013 HRS9531 seeks dual agonist differentiation<\/strong><\/td><\/tr>
GIPR Addition<\/strong><\/td>Tirzepatide’s GIP component<\/strong> may enhance lipid metabolism and vascular benefits<\/strong> vs. pure GLP-1; HRS9531 tests this hypothesis in dedicated ASCVD outcomes trial<\/strong><\/td><\/tr>
Hengrui Metabolic Franchise<\/strong><\/td>HRS9531<\/strong> anchors GLP-1\/GIP pipeline<\/strong> alongside oral formulations; cardiovascular outcomes<\/strong> indication expands beyond weight loss\/CKD<\/strong> into hard endpoint differentiation<\/strong><\/td><\/tr>
Global First-Mover<\/strong><\/td>No approved GIPR\/GLP-1R agonist for ASCVD MACE reduction<\/strong> \u2013 success would establish cardiovascular outcomes class leadership<\/strong><\/td><\/tr>
Trial Design<\/strong><\/td>Likely Phase IIb\/III cardiovascular outcomes study<\/strong> (3\u20135 year follow-up) \u2013 requires large patient population<\/strong> (n=5,000\u201310,000) and event-driven endpoint<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n